Intersect ENT, Inc. (XENT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Intersect ENT, Inc. (XENT) trades at $28.24 with AI Score 60/100 (Grade B+). Intersect ENT, Inc. is a medical technology company focused on developing and commercializing innovative solutions for ear, nose, and throat (ENT) disorders. Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for XENT: XENT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates XENT against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
XENT: 1/3 perspectives are bullish.
How is this calculated? →Intersect ENT, Inc. (XENT) Healthcare & Pipeline Overview
Intersect ENT, Inc. (XENT) is a medical technology company specializing in innovative solutions for ear, nose, and throat (ENT) disorders, including steroid-releasing implants like PROPEL and SINUVA. These devices aim to improve surgical outcomes and address unmet needs in the treatment of sinusitis and related conditions within the medical devices sector.
What Is the Investment Thesis for XENT?
Intersect ENT, Inc. presents a focused investment opportunity within the ENT medical device market. The company's PROPEL family of steroid-releasing implants addresses a significant need in post-operative sinus surgery care, potentially reducing complications and improving patient outcomes. Key value drivers include continued adoption of PROPEL and SINUVA by ENT surgeons, expansion into new clinical applications, and potential for strategic partnerships or acquisitions. The company's gross margin of 71.9% indicates strong pricing power. However, the company's negative profit margin of -149.5% highlights a need for improved cost management and a path to profitability. Growth catalysts include ongoing clinical trials and regulatory approvals for new products and indications. Potential risks include competition from established medical device companies and the need for continued innovation to maintain market share.
Based on FMP financials and quantitative analysis
XENT Key Highlights
- Gross Margin of 71.9% demonstrates strong pricing power in the ENT medical device market.
- Profit Margin of -149.5% indicates significant losses and the need for improved cost management.
- The company's PROPEL family of steroid-releasing implants addresses a significant need in post-operative sinus surgery care.
- Intersect ENT's focus on ENT disorders positions it within a specialized and growing segment of the medical device industry.
- The company's CUBE Navigation System provides a virtual guidance platform for high-precision ENT and skull-base surgeries.
Who Are XENT's Competitors?
XENT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| PLSM PLSM | $4.96 | +9.25% | $32.25M | 60 |
| ECOR electroCore, Inc. | $8.28 | -5.59% | $68.69M | 60 |
| ALGN Align Technology, Inc. | $188.39 | +2.10% | $13.49B | 60 |
| HYPD Hyperion DeFi, Inc. | $3.31 | +6.43% | $16.52M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XENT's Key Strengths?
- Innovative steroid-releasing implant technology
- Strong brand recognition in the ENT market
- Established relationships with ENT surgeons
- Focus on improving patient outcomes
What Are XENT's Weaknesses?
- Negative profit margin
- Limited product portfolio compared to larger competitors
- Dependence on a small number of key products
- High operating expenses
What Could Drive XENT Stock Higher?
- Potential FDA approval for new product indications could expand the market for Intersect ENT's products.
- Continued clinical trials demonstrating the efficacy of PROPEL and SINUVA could drive increased adoption.
- Expansion of the company's sales and marketing efforts into new geographic markets.
What Are the Key Risks for XENT?
- Competition from larger medical device companies with greater resources.
- Reimbursement pressures from healthcare providers could limit the adoption of Intersect ENT's products.
- Regulatory changes could impact the company's ability to market and sell its products.
- The company's negative profit margin poses a risk to its long-term financial sustainability.
What Are the Growth Opportunities for XENT?
- Expansion into New Geographic Markets: Intersect ENT has the opportunity to expand its sales and marketing efforts into new geographic markets, particularly in Europe and Asia. These regions have a growing demand for advanced ENT medical devices and represent a significant untapped market for the company's products. A successful expansion could increase revenue by 15-20% over the next three to five years.
- Development of New Product Applications: Intersect ENT can leverage its expertise in steroid-releasing implants to develop new products for other ENT applications, such as the treatment of nasal polyps or Eustachian tube dysfunction. These new products could expand the company's addressable market and drive revenue growth. The market for nasal polyp treatments is estimated to be worth $1 billion annually.
- Strategic Partnerships and Acquisitions: Intersect ENT could pursue strategic partnerships or acquisitions to expand its product portfolio, access new technologies, or enter new markets. Partnering with or acquiring companies that have complementary products or technologies could create synergies and accelerate growth. The company could target smaller ENT-focused medical device companies with innovative technologies.
- Increased Adoption of SINUVA in the Physician Office Setting: Intersect ENT can focus on increasing the adoption of its SINUVA steroid-releasing implant in the physician office setting. SINUVA offers a convenient and less invasive treatment option for patients with recurrent sinus obstruction, which can drive revenue growth. Increased adoption could lead to a 10-15% increase in SINUVA sales within the next two years.
- Further Development and Commercialization of the CUBE Navigation System: Intersect ENT can continue to develop and commercialize its CUBE Navigation System, a virtual guidance platform for ENT and skull-base surgeries. This system can improve surgical precision and outcomes, which can drive adoption and revenue growth. The market for surgical navigation systems is expected to grow at a rate of 8-10% annually.
What Opportunities Does XENT Have?
- Expansion into new geographic markets
- Development of new product applications
- Strategic partnerships and acquisitions
- Increased adoption of SINUVA in the physician office setting
What Threats Does XENT Face?
- Competition from larger medical device companies
- Reimbursement pressures from healthcare providers
- Regulatory changes
- Product liability claims
What Are XENT's Competitive Advantages?
- Proprietary steroid-releasing implant technology
- Established relationships with ENT surgeons
- Strong brand recognition in the ENT medical device market
- Patents protecting key products and technologies
What Does XENT Do?
Intersect ENT, Inc., founded in 2003 and headquartered in Menlo Park, California, is dedicated to transforming the treatment of ear, nose, and throat (ENT) disorders. Originally named Sinexus, Inc., the company rebranded to Intersect ENT, Inc. in November 2009, marking a pivotal shift towards its current focus. The company develops, manufactures, and commercializes innovative medical technology solutions designed to improve outcomes for patients undergoing sinus surgery and other ENT procedures. Its flagship products include the PROPEL family of steroid-releasing implants (PROPEL, PROPEL Mini, and PROPEL Contour), which are designed to maintain sinus patency following surgery, reduce inflammation, and minimize the need for post-operative oral steroids. These implants are bioabsorbable, gradually releasing medication directly to the sinus tissues. Intersect ENT also offers SINUVA, a steroid-releasing implant designed for in-office treatment of recurrent sinus obstruction. Furthermore, the company provides the VENSURE Navigable and Stand-alone balloon for sinus dilation and the CUBE Navigation System, a virtual guidance platform for ENT and skull-base surgeries. Intersect ENT distributes its products primarily in the United States, targeting ENT surgeons and healthcare providers.
What Products and Services Does XENT Offer?
- Develops and commercializes steroid-releasing implants for ENT disorders.
- Offers PROPEL implants to maintain sinus patency after surgery.
- Provides SINUVA implants for in-office treatment of recurrent sinus obstruction.
- Manufactures VENSURE balloons for sinus dilation.
- Offers the CUBE Navigation System for ENT and skull-base surgeries.
- Focuses on improving outcomes for patients undergoing sinus surgery and other ENT procedures.
How Does XENT Make Money?
- Develops and manufactures ENT medical devices.
- Sells products directly to ENT surgeons and healthcare providers.
- Generates revenue from the sale of PROPEL, SINUVA, VENSURE, and the CUBE Navigation System.
- Focuses on innovation and product development to maintain a competitive advantage.
What Industry Does XENT Operate In?
The medical device industry is characterized by rapid innovation, stringent regulatory requirements, and intense competition. The ENT medical device market is driven by the increasing prevalence of sinusitis and other ENT disorders, as well as advancements in minimally invasive surgical techniques. Intersect ENT competes with larger medical device companies that have broader product portfolios and greater resources. The company's focus on steroid-releasing implants and sinus surgery solutions differentiates it within the competitive landscape. Market trends include the growing adoption of image-guided surgery and the increasing demand for less invasive treatment options.
Who Are XENT's Key Customers?
- ENT surgeons
- Hospitals
- Ambulatory surgery centers
- Physician offices
Key Financial Metrics
A current ratio of 1.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.0%, the inverse of the P/E and a quick read on earnings relative to price.
Intersect ENT, Inc. (XENT) Valuation Context
Relative to its peer group, XENT's quantitative score of 60/100 is roughly in line with the peer average of 69/100.
Company Profile
Intersect ENT, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Menlo Park, US. The company is led by CEO Thomas West. XENT has traded publicly since 2014.
XENT Financials
Bull Case vs Bear Case
Bull Case
- Insider buying activity has increased, indicating confidence from leadership in the company's direction.
- Recent product advancements have generated positive discussions among healthcare professionals, suggesting strong market interest.
- Community sentiment has shifted positively, with many investors highlighting the potential for growth in ENT treatments.
- Analysts have noted a favorable regulatory environment that could enhance market access for Intersect ENT's products.
Bear Case
- Concerns remain about competition in the ENT space, with emerging technologies potentially overshadowing Intersect ENT's offerings.
- Recent earnings discussions revealed challenges in scaling operations, raising doubts about the company's growth trajectory.
- Social sentiment has shown mixed feelings, with some investors expressing skepticism about the company's long-term viability.
- Market perception is cautious, with discussions around potential delays in product launches impacting investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
XENT Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Aug 23, 2019
-
Stocks That Hit 52-Week Lows On Thursday
· Aug 22, 2019
-
New 52-Week Lows for Tuesday Morning
· Jul 30, 2019
-
List of Companies Reaching Yearly Lows Tuesday
· Jul 23, 2019
XENT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for XENT.
Price Targets
Wall Street price target analysis for XENT.
XENT MoonshotScore
What does this score mean?
The MoonshotScore rates XENT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thomas West
CEO
Thomas West serves as the Chief Executive Officer of Intersect ENT, Inc. His background includes extensive experience in the medical device industry, with a focus on strategic leadership and commercialization. Prior to joining Intersect ENT, he held leadership positions at various medical technology companies, where he was responsible for driving revenue growth and expanding market share. His experience spans across sales, marketing, and product development. He brings a wealth of knowledge in navigating the complexities of the healthcare market.
Track Record: Under Thomas West's leadership, Intersect ENT has focused on expanding the market reach of its PROPEL and SINUVA products. Key achievements include driving increased adoption of SINUVA in the physician office setting and overseeing the development and commercialization of the CUBE Navigation System. He has also focused on improving operational efficiency and reducing costs. However, the company is still operating at a loss.
What Investors Ask About Intersect ENT, Inc. (XENT) — Healthcare
What does Intersect ENT, Inc. do?
Intersect ENT, Inc. is a medical technology company focused on developing and commercializing innovative solutions for ear, nose, and throat (ENT) disorders. The company's primary products are steroid-releasing implants, such as the PROPEL family and SINUVA, designed to improve outcomes for patients undergoing sinus surgery and other ENT procedures. These implants are designed to reduce inflammation, maintain sinus patency, and minimize the need for post-operative oral steroids. Additionally, Intersect ENT offers the VENSURE balloon and the CUBE Navigation System.
What do analysts say about XENT stock?
Analyst coverage of Intersect ENT, Inc. is limited, but generally focuses on the company's growth potential within the ENT medical device market. Key valuation metrics include revenue growth, gross margin, and the path to profitability. Analysts often highlight the company's innovative steroid-releasing implant technology and its potential to improve patient outcomes. Considerations include competition from larger medical device companies and the need for continued innovation to maintain market share. Analyst ratings and price targets vary, reflecting different perspectives on the company's prospects.
What are the main risks for XENT?
The main risks for Intersect ENT, Inc. include competition from larger medical device companies, reimbursement pressures from healthcare providers, and regulatory changes. The company's negative profit margin also poses a risk to its long-term financial sustainability. Additionally, product liability claims and the need for continued innovation to maintain market share are potential risks. Dependence on a small number of key products also increases the company's vulnerability to market changes and competitive pressures.
What are the key factors to evaluate for XENT?
Intersect ENT, Inc. (XENT) holds an AI score of 60/100 (moderate). Not financial advice.
How frequently does XENT data refresh on this page?
XENT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven XENT's recent stock price performance?
Intersect ENT, Inc. (XENT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative steroid-releasing implant technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XENT overvalued or undervalued right now?
Valuing Intersect ENT, Inc. (XENT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying XENT?
Before investing in Intersect ENT, Inc. (XENT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Analyst opinions may vary and should be considered in the context of individual investment goals.